Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vl Biotech Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are being handled by 2 distinct examiners. This means that each pending matter is assigned to a different person, preventing any single examiner from managing the entire portfolio.
The portfolio is active in 2 distinct art units. This indicates that the 2 pending actions are being reviewed in different technical divisions of the patent office. This distribution suggests that the company's current filings cover diverse technical subject matter within its field.
PAULUS, ERIN VIRGINIA is the busiest examiner for the company. This examiner is responsible for 1 pending office action. Since there are 2 pending actions and 2 distinct examiners, each examiner is currently managing 1 action. This equal distribution of work ensures that the busiest examiner's influence is limited to one application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| KANE, TREVOR LOGAN | 1 | 69.4% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18429193 | mRNA NANOCAPSULE | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18185231 | COMPOSITIONS AND METHODS FOR REDUCING URIC ACID CONCENTRATION USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM | KANE, TREVOR LOGAN | 46d |
| 18429193 | mRNA NANOCAPSULE | PAULUS, ERIN VIRGINIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18429193 | mRNA NANOCAPSULE | PAULUS, ERIN VIRGINIA | 1631 | §103 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18185231 | COMPOSITIONS AND METHODS FOR REDUCING URIC ACID CONCENTRATION USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM | KANE, TREVOR LOGAN | 1657 | §103 | Final Rejection | 46d | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial